Literature DB >> 1015532

Squamous cell carcinoma of the oropharynx: why we fail.

R H Jesse, E V Sugarbaker.   

Abstract

The squamous cancers of the oropharynx in 384 patients were staged according to a T and N system. Three hundred seventy-one of them were treated for cure at a time when modern surgical and radiotherapeutic technics were available. The patient records were analyzed in regard to five year survival, factors influencing treatment failure, and the effect of new primary cancers. Failure to eradicate the cancer at the primary site remains the largest reason for the patients' demise, but as aggressive local and regional treatment becomes more successful, greater numbers of patients survive only to become victims of distant metastases and second primary cancers.

Entities:  

Mesh:

Year:  1976        PMID: 1015532     DOI: 10.1016/0002-9610(76)90314-7

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  15 in total

1.  Second malignant tumours in head and neck cancer.

Authors:  G R Ogden
Journal:  BMJ       Date:  1991-01-26

2.  Neck dissection alternatives.

Authors:  R M Tiwari
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  1997-10

Review 3.  Molecular margins in head and neck cancer: Current techniques and future directions.

Authors:  Katelyn O Stepan; Michael M Li; Stephen Y Kang; Sidharth V Puram
Journal:  Oral Oncol       Date:  2020-07-20       Impact factor: 5.337

4.  Detection of human brain tumor infiltration with quantitative stimulated Raman scattering microscopy.

Authors:  Minbiao Ji; Spencer Lewis; Sandra Camelo-Piragua; Shakti H Ramkissoon; Matija Snuderl; Sriram Venneti; Amanda Fisher-Hubbard; Mia Garrard; Dan Fu; Anthony C Wang; Jason A Heth; Cormac O Maher; Nader Sanai; Timothy D Johnson; Christian W Freudiger; Oren Sagher; Xiaoliang Sunney Xie; Daniel A Orringer
Journal:  Sci Transl Med       Date:  2015-10-14       Impact factor: 17.956

5.  [Preoperative radiochemotherapy for advanced oral cavity tumours : the Kiel DOSAK experience regarding curability and quality of life].

Authors:  Jürgen Schultze; Helge Schillmöller; J Camilo Roldán; Jörg Wiltfang; Bernhard Kimmig
Journal:  Mund Kiefer Gesichtschir       Date:  2006-07

6.  Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma.

Authors:  Oleksandr Ekshyyan; Youhua Rong; Xiaohua Rong; Kavita M Pattani; Fleurette Abreo; Gloria Caldito; John Kai Siung Chang; Federico Ampil; Jonathan Glass; Cherie-Ann O Nathan
Journal:  Mol Cancer Ther       Date:  2009-07-22       Impact factor: 6.261

7.  Autoantibody approach for serum-based detection of head and neck cancer.

Authors:  Ho-Sheng Lin; Harvinder S Talwar; Adi L Tarca; Alexei Ionan; Madhumita Chatterjee; Bin Ye; Jerzy Wojciechowski; Saroj Mohapatra; Marc D Basson; George H Yoo; Brian Peshek; Fulvio Lonardo; Chuan-Ju G Pan; Adam J Folbe; Sorin Draghici; Judith Abrams; Michael A Tainsky
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-11       Impact factor: 4.254

8.  A nationwide study of the epidemiology, treatment and survival of oropharyngeal carcinoma in The Netherlands.

Authors:  S Mak-Kregar; F J Hilgers; P C Levendag; J J Manni; H Lubsen; J L Roodenburg; J M van der Beek; A G van der Meij
Journal:  Eur Arch Otorhinolaryngol       Date:  1995       Impact factor: 2.503

Review 9.  Margin Analysis in Head and Neck Cancer: State of the Art and Future Directions.

Authors:  Michael M Li; Sidharth V Puram; Dustin A Silverman; Matthew O Old; James W Rocco; Stephen Y Kang
Journal:  Ann Surg Oncol       Date:  2019-08-05       Impact factor: 5.344

Review 10.  Supracricoid partial laryngectomy for radiorecurrent laryngeal cancer: a systematic review of the literature and meta-analysis.

Authors:  Armando De Virgilio; Raul Pellini; Giuseppe Mercante; Giovanni Cristalli; Valentina Manciocco; Diana Giannarelli; Giuseppe Spriano
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-04-30       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.